These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37479613)

  • 1. Computational design of mRNA vaccines.
    Kim YA; Mousavi K; Yazdi A; Zwierzyna M; Cardinali M; Fox D; Peel T; Coller J; Aggarwal K; Maruggi G
    Vaccine; 2024 Mar; 42(7):1831-1840. PubMed ID: 37479613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune responses related to the immunogenicity and reactogenicity of COVID-19 mRNA vaccines.
    Matsumura T; Takano T; Takahashi Y
    Int Immunol; 2023 May; 35(5):213-220. PubMed ID: 36566501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knife's edge: Balancing immunogenicity and reactogenicity in mRNA vaccines.
    Lee J; Woodruff MC; Kim EH; Nam JH
    Exp Mol Med; 2023 Jul; 55(7):1305-1313. PubMed ID: 37430088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mRNA vaccines for COVID-19: what, why and how.
    Park JW; Lagniton PNP; Liu Y; Xu RH
    Int J Biol Sci; 2021; 17(6):1446-1460. PubMed ID: 33907508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspectives and Prospects on mRNA Vaccine Development for COVID-19.
    Jin L; Han Z; Zhao P; Sun K
    Curr Med Chem; 2022; 29(23):3991-3996. PubMed ID: 35170403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases.
    Rouf NZ; Biswas S; Tarannum N; Oishee LM; Muna MM
    RNA Biol; 2022; 19(1):386-410. PubMed ID: 35354425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dawn of mRNA vaccines: The COVID-19 case.
    Verbeke R; Lentacker I; De Smedt SC; Dewitte H
    J Control Release; 2021 May; 333():511-520. PubMed ID: 33798667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Algorithm for optimized mRNA design improves stability and immunogenicity.
    Zhang H; Zhang L; Lin A; Xu C; Li Z; Liu K; Liu B; Ma X; Zhao F; Jiang H; Chen C; Shen H; Li H; Mathews DH; Zhang Y; Huang L
    Nature; 2023 Sep; 621(7978):396-403. PubMed ID: 37130545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 mRNA vaccines: Platforms and current developments.
    Szabó GT; Mahiny AJ; Vlatkovic I
    Mol Ther; 2022 May; 30(5):1850-1868. PubMed ID: 35189345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances of Reverse Vaccinology for mRNA Vaccine Design against SARS-CoV-2: A Review of Methods and Tools.
    da Silva MK; Campos DMO; Akash S; Akter S; Yee LC; Fulco UL; Oliveira JIN
    Viruses; 2023 Oct; 15(10):. PubMed ID: 37896907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mRNA Vaccine Revolution: COVID-19 Has Launched the Future of Vaccinology.
    Ye Z; Harmon J; Ni W; Li Y; Wich D; Xu Q
    ACS Nano; 2023 Aug; 17(16):15231-15253. PubMed ID: 37535899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can the triumph of mRNA vaccines against COVID-19 be extended to other viral infections of humans and domesticated animals?
    Sehrawat S; Osterrieder N; Schmid DS; Rouse BT
    Microbes Infect; 2023; 25(1-2):105078. PubMed ID: 36435367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioengineering of Novel Non-Replicating mRNA (NRM) and Self-Amplifying mRNA (SAM) Vaccine Candidates Against SARS-CoV-2 Using Immunoinformatics Approach.
    Bhattacharya M; Sharma AR; Ghosh P; Patra P; Patra BC; Lee SS; Chakraborty C
    Mol Biotechnol; 2022 May; 64(5):510-525. PubMed ID: 34981440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mRNA vaccines for COVID-19 and diverse diseases.
    Hussain A; Yang H; Zhang M; Liu Q; Alotaibi G; Irfan M; He H; Chang J; Liang XJ; Weng Y; Huang Y
    J Control Release; 2022 May; 345():314-333. PubMed ID: 35331783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines.
    Guo X; Liu D; Huang Y; Deng Y; Wang Y; Mao J; Zhou Y; Xiong Y; Gao X
    Virol J; 2023 Apr; 20(1):64. PubMed ID: 37029389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mRNA vaccine, a swift warhead against a moving infectious disease target.
    Mir S; Mir M
    Expert Rev Vaccines; 2024; 23(1):336-348. PubMed ID: 38369742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic.
    Chen P; Shi X; He W; Zhong G; Tang Y; Wang H; Zhang P
    Hum Vaccin Immunother; 2022 Dec; 18(1):2040330. PubMed ID: 35321627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Development of mRNA Vaccines: Challenges and Opportunities.
    August A; Brito L; Paris R; Zaks T
    Curr Top Microbiol Immunol; 2022; 440():167-186. PubMed ID: 35906319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.